Antibacterial Mouthwash for Gonorrhea Prevention
Trial Summary
What is the purpose of this trial?
This study aims to determine acceptability and preliminary efficacy of daily use of an antibacterial mouthwash as compared to a placebo mouthwash in reducing the incidence of pharyngeal gonorrhea among a cohort of HIV-positive and high risk HIV-negative men. Investigators plan to test the following hypotheses: 1. Participants will maintain a high level of adherence and satisfaction with daily mouthwash use. Furthermore, the investigators hypothesize that barriers to adherence will include structural factors such as unstable housing and individual level factors such as substance use. 2. Participants receiving the antibacterial mouthwash will have a lower incidence of pharyngeal gonorrhea as compared to participants receiving the placebo mouthwash. Furthermore, the investigators hypothesize that these reductions will remain even after adjusting for other factors such as HIV-status and substance use.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you will need to stop using your current mouthwash during the 24-week study period.
What data supports the effectiveness of the treatment Biotene Mouthwash, Listerine Antiseptic Mouthwash Product for preventing gonorrhea?
Is antibacterial mouthwash safe for humans?
How does Biotene Mouthwash differ from other treatments for gonorrhea prevention?
Biotene Mouthwash is unique because it is being studied as a preventive treatment for gonorrhea, specifically targeting the throat area, which is not a standard approach for this condition. Unlike traditional antibiotic treatments, it is a non-drug option that may help reduce the risk of infection through regular oral hygiene practices.125910
Research Team
Marjan Javanbakht
Principal Investigator
University of California, Los Angeles
Eligibility Criteria
This trial is for HIV-positive and high-risk HIV-negative men who have had unprotected anal intercourse in the past 6 months. Participants must be willing to attend follow-up visits, provide consent, and share contact information. They should be aged 18-45, biologically male at birth, and previously diagnosed with pharyngeal gonorrhea.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Phase 1
Participants receive either antibacterial mouthwash or placebo for 12 weeks
Treatment Phase 2
Participants crossover to the alternate mouthwash (antibacterial or placebo) for another 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Biotene Mouthwash
- Listerine Antiseptic Mouthwash Product
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator